{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T05:27:36Z","timestamp":1732080456832,"version":"3.28.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Medical Association"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jnma.2023.11.009","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T04:41:20Z","timestamp":1703392880000},"page":"508-516","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lp(a) and risk of cardiovascular disease \u2013 A review of existing evidence and emerging concepts"],"prefix":"10.1016","volume":"116","author":[{"given":"Manasa","family":"Jasti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Steele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willibroad","family":"Maimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ijeoma","family":"Isiadinso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jnma.2023.11.009_bib0001","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jnma.2023.11.009_bib0002","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","article-title":"Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis","volume":"35","author":"Guan","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.jnma.2023.11.009_bib0003","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/1047-2797(94)90067-1","article-title":"Concentrations of Lp(a) in black and white young adults: relations to risk factors for cardiovascular disease","volume":"4","author":"Howard","year":"1994","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.jnma.2023.11.009_bib0004","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2013the Lp system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"1","key":"10.1016\/j.jnma.2023.11.009_bib0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/0004563220968473","article-title":"Lp(a): when and how to measure it","volume":"58","author":"Cegla","year":"2021","journal-title":"Ann Clin Biochem"},{"issue":"7","key":"10.1016\/j.jnma.2023.11.009_bib0006","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review","volume":"7","author":"Duarte Lau","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.jnma.2023.11.009_bib0007","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jama.2021.3632","article-title":"Lipoprotein(a) and cardiovascular diseases","volume":"326","author":"Miksenas","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jnma.2023.11.009_bib0008","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1590\/S0100-879X1997001100002","article-title":"Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process","volume":"30","author":"Angl\u00e9s-Cano","year":"1997","journal-title":"Braz J Med Biol Res"},{"issue":"6","key":"10.1016\/j.jnma.2023.11.009_bib0009","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jnma.2023.11.009_bib0010","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.jnma.2023.11.009_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/biom12010026","article-title":"Lipoprotein(a)-the crossroads of atherosclerosis, atherothrombosis and inflammation","volume":"12","author":"Ugov\u0161ek","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.jnma.2023.11.009_bib0012","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.jnma.2023.11.009_bib0013","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1038\/s41598-022-07596-4","article-title":"Elevated lipoprotein(a) and genetic polymorphisms in the LPA gene may predict cardiovascular events","volume":"12","author":"Gu","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jnma.2023.11.009_bib0014","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.jnma.2023.11.009_bib0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12881-020-01003-3","article-title":"Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification","volume":"21","author":"Pechlivanis","year":"2020","journal-title":"BMC Med Genet"},{"issue":"24","key":"10.1016\/j.jnma.2023.11.009_bib0016","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the american college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jnma.2023.11.009_bib0017","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce Lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jnma.2023.11.009_bib0018","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol"},{"issue":"4","key":"10.1016\/j.jnma.2023.11.009_bib0019","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jnma.2023.11.009_bib0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2022.04.005","article-title":"Lipoprotein(a) and ethnicities","volume":"349","author":"Mehta","year":"2022","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.jnma.2023.11.009_bib0021","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.jnma.2023.11.009_bib0022","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1161\/CIRCULATIONAHA.108.836940","article-title":"Relationship of oxidized phospholipids on Apolipoprotein B-100 particles to race\/ethnicity, Apolipoprotein(a) isoform size, and cardiovascular risk factors","volume":"119","author":"Tsimikas","year":"2009","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jnma.2023.11.009_bib0023","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jnma.2023.11.009_bib0024","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jnma.2023.11.009_bib0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/164_2021_504","article-title":"Lipoprotein(a)","volume":"270","author":"Kronenberg","year":"2022","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"10.1016\/j.jnma.2023.11.009_bib0026","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0735-1097(00)01126-8","article-title":"Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk","volume":"37","author":"von Eckardstein","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jnma.2023.11.009_bib0027","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.jnma.2023.11.009_bib0028","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"33","key":"10.1016\/j.jnma.2023.11.009_bib0029","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jnma.2023.11.009_bib0030","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jnma.2023.11.009_bib0031","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/jamacardio.2017.4266","article-title":"Association of LPA variants with aortic stenosis: a large-scale study using diagnostic and procedural codes from electronic health records","volume":"3","author":"Chen","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.jnma.2023.11.009_bib0032","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jnma.2023.11.009_bib0033","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jnma.2023.11.009_bib0034","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, Lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jnma.2023.11.009_bib0035","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamacardio.2018.3798","article-title":"Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: secondary Analysis of a Randomized Clinical Trial","volume":"3","author":"Capoulade","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.jnma.2023.11.009_bib0036","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"issue":"7","key":"10.1016\/j.jnma.2023.11.009_bib0037","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for Lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiology"},{"issue":"6","key":"10.1016\/j.jnma.2023.11.009_bib0038","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.hjc.2020.09.016","article-title":"The role of Lipoprotein(a) in cardiovascular disease: current concepts and future perspectives","volume":"61","author":"Vavuranakis","year":"2020","journal-title":"Hellenic J Cardiol"},{"issue":"1","key":"10.1016\/j.jnma.2023.11.009_bib0039","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated Lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.jnma.2023.11.009_bib0040","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jnma.2023.11.009_bib0041","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jnma.2023.11.009_bib0042","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"3","key":"10.1016\/j.jnma.2023.11.009_bib0043","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jnma.2023.11.009_bib0044","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on Lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jnma.2023.11.009_bib0045","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood-2006-01-010645","article-title":"Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions","volume":"109","author":"Undas","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jnma.2023.11.009_bib0046","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"issue":"14","key":"10.1016\/j.jnma.2023.11.009_bib0047","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to Lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.jnma.2023.11.009_bib0048","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"issue":"8a","key":"10.1016\/j.jnma.2023.11.009_bib0049","doi-asserted-by":"crossref","first-page":"20b","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"issue":"17","key":"10.1016\/j.jnma.2023.11.009_bib0050","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jnma.2023.11.009_bib0051","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2147\/VHRM.S266244","article-title":"Elevated Lipoprotein(a): background, Current Insights and Future Potential Therapies","volume":"17","author":"Handhle","year":"2021","journal-title":"Vasc Health Risk Manag"},{"issue":"20","key":"10.1016\/j.jnma.2023.11.009_bib0052","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jnma.2023.11.009_bib0053","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jnma.2023.11.009_bib0054","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/cvr\/cvab247","article-title":"The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors","volume":"118","author":"Blanchard","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"27","key":"10.1016\/j.jnma.2023.11.009_bib0055","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jnma.2023.11.009_bib0056","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.jnma.2023.11.009_bib0057","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jnma.2023.11.009_bib0058","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jnma.2023.11.009_bib0059","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of Alirocumab on Lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jnma.2023.11.009_bib0060","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jnma.2023.11.009_bib0061","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting Lipoprotein(a) production in individuals with elevated plasma Lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jnma.2023.11.009_bib0062","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the Olpasiran trials of cardiovascular events and LipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)","volume":"251","author":"O'Donoghue","year":"2022","journal-title":"Am Heart J"},{"issue":"10002","key":"10.1016\/j.jnma.2023.11.009_bib0063","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jnma.2023.11.009_bib0064","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"10057","key":"10.1016\/j.jnma.2023.11.009_bib0065","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jnma.2023.11.009_bib0066","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","article-title":"Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2\/4","volume":"77","author":"Tsimikas","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jnma.2023.11.009_bib0067","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apher"},{"issue":"Suppl 1","key":"10.1016\/j.jnma.2023.11.009_bib0068","first-page":"44","article-title":"The German lipoprotein apheresis registry (GLAR) - almost 5 years on","volume":"12","author":"Schettler","year":"2017","journal-title":"Clin Res CardiolSuppl"},{"issue":"24","key":"10.1016\/j.jnma.2023.11.009_bib0069","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jnma.2023.11.009_bib0070","first-page":"413","article-title":"Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review","volume":"14","author":"Franchini","year":"2016","journal-title":"Blood Transfus"}],"container-title":["Journal of the National Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027968423001414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027968423001414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T11:08:18Z","timestamp":1732014498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0027968423001414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0027968423001414"],"URL":"https:\/\/doi.org\/10.1016\/j.jnma.2023.11.009","relation":{},"ISSN":["0027-9684"],"issn-type":[{"type":"print","value":"0027-9684"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lp(a) and risk of cardiovascular disease \u2013 A review of existing evidence and emerging concepts","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnma.2023.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 National Medical Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}